6-amino-1-hydroxyhexane-1,1-diphosphonate has been researched along with Osteogenesis Imperfecta in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Celli, M; Cipriani, C; Colangelo, L; Diacinti, D; Iannacone, A; Kripa, E; Minisola, S; Nieddu, L; Pepe, J; Pisani, D; Zambrano, A | 1 |
| Adami, G; Antoniazzi, F; Bertoldo, F; Fassio, A; Gatti, D; Idolazzi, L; Rossini, M; Viapiana, O | 1 |
| Celli, L; Celli, M; D'Alfonso, Y; D'Eufemia, P; Febbo, A; Persiani, P; Turchetti, A; Zambrano, A | 1 |
| Celli, M; D'Eufemia, P; Finocchiaro, R; Lodato, V; Palombaro, M; Properzi, E; Villani, C; Zambrano, A | 1 |
| Cassens, J; Höbing, L; Hoyer-Kuhn, H; Schoenau, E; Semler, O | 1 |
| Celli, L; Celli, M; D'Eufemia, P; Finocchiaro, R; Finocchiaro, S; Lodato, V; Persiani, P; Turchetti, A; Zambrano, A | 1 |
| Adami, G; Bertoldo, F; Fassio, A; Gatti, D; Idolazzi, L; Orsolini, G; Rossini, M; Viapiana, O | 1 |
| Adami, S; Fracassi, E; Gatti, D; Idolazzi, L; Viapiana, O | 1 |
| Beccard, R; Demant, A; Fricke, O; Koerber, F; Palmisano, D; Schoenau, E; Semler, O | 1 |
| Antoniazzi, F; Cavarzere, P; Doro, F; Maines, E; Monti, E; Morandi, G | 1 |
| Adami, S; Braga, V; Colapietro, F; Fracassi, E; Gatti, D; Rossini, M; Tatò, L | 1 |
| Adami, S; Antoniazzi, F; Braga, V; Gatti, D; Prizzi, R; Rossini, M; Tatò, L; Viapiana, O | 1 |
| Adami, S; Braga, V; Gatti, D; Lippolis, I; Prizzi, R; Rossini, M; Viapiana, O | 1 |
| Adami, S; Antoniazzi, F; Donadi, L; Lauriola, S; Tatò, L; Zamboni, G | 1 |
| Celli, M; D'Eufemia, P; Ferrucci, V; Finocchiaro, R; Tetti, M; Zambrano, A | 1 |
| Antoniazzi, F; Carli, M; Monti, E; Pietrobelli, A; Rugolotto, S; Tato, L | 1 |
| Celli, M; D'Eufemia, P; Finocchiaro, R; Mari, E; Persiani, P; Tetti, M; Villani, C; Zambrano, A; Zicari, A | 1 |
1 review(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Osteogenesis Imperfecta
| Article | Year |
|---|---|
Neridronic acid for the treatment of bone metabolic diseases.
Topics: Adult; Bone Diseases, Metabolic; Child; Child, Preschool; Clinical Trials as Topic; Diphosphonates; Drug Evaluation, Preclinical; Humans; Infant; Infant, Newborn; Italy; Osteitis Deformans; Osteogenesis Imperfecta | 2009 |
6 trial(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Osteogenesis Imperfecta
| Article | Year |
|---|---|
Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study.
Topics: Adolescent; Bone and Bones; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Humans; Italy; Male; Osteogenesis Imperfecta | 2017 |
Serum creatine kinase isoenzymes in children with osteogenesis imperfecta.
Topics: Biomarkers; Bone Density Conservation Agents; Child; Child, Preschool; Clinical Enzyme Tests; Creatine Kinase; Diphosphonates; Drug Monitoring; Female; Follow-Up Studies; Humans; Isoenzymes; Male; Osteogenesis Imperfecta | 2017 |
Intravenous neridronate in adults with osteogenesis imperfecta.
Topics: Adult; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Collagen; Collagen Type I; Diphosphonates; Female; Fractures, Bone; Humans; Infusions, Intravenous; Male; Middle Aged; Osteogenesis Imperfecta; Peptides | 2003 |
Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Topics: Alkaline Phosphatase; Body Height; Bone and Bones; Bone Density; Child; Diphosphonates; Female; Fractures, Bone; Humans; Infusions, Intravenous; Male; Osteogenesis Imperfecta; Prospective Studies; Risk; Time Factors | 2005 |
Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Adult; Bone and Bones; Bone Density; Calcium; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Injections, Intravenous; Male; Osteogenesis Imperfecta; Radius; Tomography, X-Ray Computed; Vitamin D | 2005 |
Early bisphosphonate treatment in infants with severe osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Anthropometry; Calcium; Diphosphonates; Drug Administration Schedule; Early Diagnosis; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Infant; Infant, Newborn; Lumbar Vertebrae; Male; Osteocalcin; Osteogenesis Imperfecta; Phosphates; Prevalence; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2006 |
10 other study(ies) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Osteogenesis Imperfecta
| Article | Year |
|---|---|
Vertebral fracture assessment (VFA) for monitoring vertebral reshaping in children and adolescents with osteogenesis imperfecta treated with intravenous neridronate.
Topics: Absorptiometry, Photon; Adolescent; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Humans; Infant; Male; Osteogenesis Imperfecta; Spinal Fractures | 2021 |
Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Topics: Adolescent; Bone Density Conservation Agents; Diphosphonates; Humans; Low Density Lipoprotein Receptor-Related Protein-5; Male; Mutation; Osteogenesis Imperfecta; Osteoporotic Fractures; Radiography; Spinal Fractures | 2017 |
Serum brain-type creatine kinase increases in children with osteogenesis imperfecta during neridronate treatment.
Topics: Bone Resorption; Child; Child, Preschool; Creatine Kinase, BB Form; Densitometry; Diphosphonates; Female; Gene Expression Regulation, Enzymologic; Humans; Infusions, Intravenous; Male; Osteoclasts; Osteogenesis Imperfecta; Risk | 2014 |
Children with severe Osteogenesis imperfecta and short stature present on average with normal IGF-I and IGFBP-3 levels.
Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Diphosphonates; Female; Growth Disorders; Hospitals, Pediatric; Hospitals, University; Humans; Infant; Infusions, Intravenous; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Osteogenesis Imperfecta; Outpatient Clinics, Hospital; Retrospective Studies; Severity of Illness Index | 2016 |
Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Bone and Bones; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Italy; Male; Osteogenesis Imperfecta; Time; Treatment Outcome | 2017 |
Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Adolescent; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Case-Control Studies; Child; Child, Preschool; Cohort Studies; Diphosphonates; Female; Humans; Infant; Infant, Newborn; Male; Osteogenesis Imperfecta; Pamidronate; Retrospective Studies; Spine | 2011 |
Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw.
Topics: Adolescent; Adult; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Incidence; Infusions, Intravenous; Italy; Male; Osteogenesis Imperfecta; Retrospective Studies; Risk; Severity of Illness Index; Time Factors; Young Adult | 2012 |
Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
Topics: Amino Acids; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Humans; Male; Osteogenesis Imperfecta; Taurine | 2007 |
Pulmonary function tests in an infant with osteogenesis imperfecta and early biphosphonate treatment.
Topics: Bone Density Conservation Agents; Diphosphonates; Fatal Outcome; Female; Humans; Infant; Osteogenesis Imperfecta; Point Mutation; Respiratory Function Tests; Respiratory Insufficiency | 2007 |
High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment.
Topics: Bone and Bones; Catalysis; Child; Child, Preschool; Cyclooxygenase 2; Dinoprostone; Diphosphonates; Female; Humans; Infant; Inflammation; Male; Models, Biological; Osteogenesis Imperfecta | 2008 |